[待更新] Ipsen Bioinnovation (formerly Syntaxin)
In March 2015, Syntaxin has changed its name to Ipsen Bioinnovation.
Ipsen Bioinnovation is a leader in recombinant botulinum toxin technology. This R&D center has an expertise in natural and modified recombinant botulinum toxins, and in targeted secretion inhibitors or retargeted molecules. ion & performance Equal opportunity and diversity Join the Ipsen Group Investors Ipsen shares Stock...
